Similarly, this prognostic effect was also found for OS (RR = 0.28; p = 0.004), DSS (RR = 0.32; p = 0.011), and RFS (RR = 0.36; p = 0.024) in the CCL5 IC-negative subgroup of patients in the tumor stage pT3 + 4 subgroup for OS (RR = 0.25; p = 0.023), DSS (RR = 0.29; p = 0.041), and RFS (RR = 0.23; p = 0.020). This evidence concerns the gene CCL5 and neoplasm.